Last reviewed · How we verify
Combined antioxidant therapy
Combined antioxidant therapy is a Antioxidant combination therapy Small molecule drug developed by University of Guadalajara. It is currently in Phase 3 development. Also known as: Drusen Laz, lutein, zeaxanthin, astaxanthin.
Combined antioxidant therapy works by neutralizing reactive oxygen species and reducing oxidative stress through multiple complementary antioxidant pathways.
Combined antioxidant therapy has been studied in various conditions, including Carotid Stenosis, Cardiovascular Disease, Atherosclerosis, Stroke, and Infertility in males, with interventions such as Aspirin, aspirin plus dipyridamole, and intake of antioxidant supplements. The mechanism of action of some antioxidant supplements is related to the inhibition of 2'-deoxyadenosine hydrolytic enzyme, a hydrolytic enzyme.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Combined antioxidant therapy |
|---|---|
| Also known as | Drusen Laz, lutein, zeaxanthin, astaxanthin, vitamin C |
| Sponsor | University of Guadalajara |
| Drug class | Antioxidant combination therapy |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
This therapeutic approach combines multiple antioxidant agents to scavenge free radicals and enhance endogenous antioxidant defenses, thereby reducing cellular damage from oxidative stress. By targeting oxidative stress through synergistic mechanisms, the combination aims to provide broader protection against conditions where oxidative damage is pathogenic. The specific antioxidant agents and their targets within this combination are not publicly detailed.
Approved indications
Common side effects
Key clinical trials
- Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity (PHASE2)
- Ascorbate in Myelodysplastic Syndrome (PHASE2)
- High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML) (PHASE1)
- The Effectiveness of Herbal Creams Compared to Urea in Dry Skin Treatment (PHASE1, PHASE2)
- The Efficacy of Selenium as an Alternative or Complementary Topical Treatment of Oral Lichen Planus (PHASE4)
- A Study to See Whether Taking a Mix of Vitamins Can Help Adults Recover Better After Surgery for Carpal Tunnel Syndrome (NA)
- Improving Exercise Rehabilitation Efficacy Outcomes Veterans Peripheral Artery Disease (NA)
- Effect of a Combined Exercise and Anti-Inflammatory Nutritional Intervention in Frail Older Adults (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combined antioxidant therapy CI brief — competitive landscape report
- Combined antioxidant therapy updates RSS · CI watch RSS
- University of Guadalajara portfolio CI
Frequently asked questions about Combined antioxidant therapy
What is Combined antioxidant therapy?
How does Combined antioxidant therapy work?
Who makes Combined antioxidant therapy?
Is Combined antioxidant therapy also known as anything else?
What drug class is Combined antioxidant therapy in?
What development phase is Combined antioxidant therapy in?
Related
- Drug class: All Antioxidant combination therapy drugs
- Manufacturer: University of Guadalajara — full pipeline
- Also known as: Drusen Laz, lutein, zeaxanthin, astaxanthin, vitamin C
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing